Chief Accounting Officer · Phathom Pharmaceuticals, Inc. (PHAT)

Anthony Guzzo

FY2021 is the first fiscal year CompBrief holds for Anthony Guzzo as a named executive officer of Phathom Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,365,153

Salary $319,271Stock awards $326,275Bonus $22,911

3rd of 3 named executive officers at Phathom Pharmaceuticals by FY2021 total.

3 named officers on file for Phathom Pharmaceuticals, FY2021

Anthony Guzzo’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • PHAT’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Phathom Pharmaceuticals’s whole pay program stands against its peers

  • Phathom Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PHAT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 12, 2022 (DEF 14A).

Free

Get Anthony Guzzo’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anthony Guzzo compensation by year

Phathom Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Phathom Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$319,271
Bonus$22,911
Stock awards$326,275
Option awards$570,605
Non-equity incentive$111,466
Pension and deferred compensation$0
All other$14,625
Total$1,365,153

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Phathom Pharmaceuticals, Inc. DEF 14A filed April 12, 2022, accession 0000950170-22-005595, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Phathom Pharmaceuticals, Inc. filed document, accession 0000950170-22-005595. Every figure is read from that document and cited to the page and table it appears in. Filed April 12, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
PSU10,000$196,700—
PSU7,500$147,525—
PSU2,500$49,175—
PSU1,000$19,670—
Option7,750—$32.20
Option24,250—$39.11
Option32,344—$25.06

Per the Outstanding Equity Awards at Fiscal Year-End table in Phathom Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Phathom Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Terrie CurranPresident and Chief Executive Officer$6,272,655
Azmi NabulsiChief Operating Officer$4,321,236
Anthony Guzzo · this pageChief Accounting Officer$1,365,153

The full Phathom Pharmaceuticals compensation record

free company brief

This page is one person within Phathom Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Phathom Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Phathom Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anthony Guzzo's compensation dossier · One-time report. No refunds.